| Assessment Status | Rapid review complete |
| HTA ID | 21044 |
| Drug | Zanubrutinib |
| Brand | Brukinsa® |
| Indication | Monotherapy for the treatment of adult patients with Waldenström’s macroglobulinaemia who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy |
| Assessment Process | |
| Rapid review commissioned | 11/10/2021 |
| Rapid review completed | 16/11/2021 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that zanubrutinib (Brukinsa®) not be considered for reimbursement at the submitted price* |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013
